Evaluation and treatment of patients with progressive immunosuppression
    2.
    发明授权
    Evaluation and treatment of patients with progressive immunosuppression 失效
    进行性免疫抑制患者的评估和治疗

    公开(公告)号:US5583002A

    公开(公告)日:1996-12-10

    申请号:US987966

    申请日:1992-12-11

    摘要: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels and T-lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, or a protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.

    摘要翻译: 存在于源自荷瘤哺乳动物的血清中的可溶性免疫抑制因子与TCR蛋白亚基水平和T淋巴细胞信号转导途径蛋白质的变化相关。 这些变化提供了通过确定至少一种选择的TCR亚单位蛋白或T淋巴细胞信号转导途径中的蛋白质的表达水平,并将其水平与非淋巴细胞中发现的水平进行比较来确定哺乳动物免疫抑制水平的方法, 免疫抑制个体。 该方法可用于鉴定具有能够激活免疫治疗的T淋巴细胞的患者和用于鉴定引起或逆转免疫抑制的药物。 与蛋白质表达水平相关的分离的免疫抑制因子可用于抑制免疫应答,例如在器官移植中。